0001193125-23-156724.txt : 20230530 0001193125-23-156724.hdr.sgml : 20230530 20230530172001 ACCESSION NUMBER: 0001193125-23-156724 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230530 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230530 DATE AS OF CHANGE: 20230530 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-28386 FILM NUMBER: 23977830 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 8-K 1 d480208d8k.htm 8-K 8-K
CTI BIOPHARMA CORP NASDAQ false 0000891293 0000891293 2023-05-30 2023-05-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 30, 2023

 

 

CTI BIOPHARMA CORP.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-28386   91-1533912

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

3101 Western Avenue, Suite 800

Seattle, Washington 98121

(Address of principal executive offices, including Zip Code)

(206) 282-7100

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☒

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001   CTIC   Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01.

Other Events.

On May 30, 2023, CTI Biopharma Corp., a Delaware corporation (“CTI”), issued a press release, a copy of which is furnished as Exhibit 99.1 and incorporated by reference into this Item 8.01, announcing that it has canceled the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) which was scheduled for June 21, 2023, and has withdrawn the proposals to have been submitted to stockholders at the Annual Meeting.

The Annual Meeting has been canceled due to the ongoing tender offer by Cleopatra Acquisition Corp., a Delaware corporation (“Purchaser”) and an indirect, wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ), a Swedish public limited liability company (“Sobi”), to acquire all of the outstanding shares of CTI common stock pursuant to the Agreement and Plan of Merger, dated as of May 10, 2023, by and among CTI, Sobi and Purchaser (as it may be amended from time to time, the “Merger Agreement,” and the transactions contemplated thereunder, the “Merger”). If the Merger is not consummated pursuant to the terms of the Merger Agreement, CTI will reschedule the Annual Meeting for a later date.

The Merger is expected to close by the third quarter of 2023, subject to customary closing conditions. CTI expects that the current members of the Board Of Directors will continue as directors until the closing of the transaction. Upon the closing of the transaction, CTI common stock will no longer be listed on any public market.

Important Information

The tender offer described in this communication commenced on May 25, 2023. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of CTI common stock. On May 25, 2023, Sobi and Purchaser filed with the U.S. Securities and Exchange Commission (the “SEC”) a Tender Offer Statement on Schedule TO, and CTI filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. CTI STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION WHICH SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders of CTI at no expense to them. Stockholders may obtain free copies of the Tender Offer Statement and the Solicitation/Recommendation Statement, as each may be supplemented from time to time, and other documents filed by the parties at the SEC’s website at www.sec.gov. Additional copies may be obtained for free by contacting Sobi or CTI. Free copies of these materials and certain other offering documents will be made available by CTI in response to requests by mail to CTI BioPharma Corp., 3101 Western Ave #800, Seattle, WA 98121, Attention: Investor Relations, by email at invest@ctibiopharm.com, or by directing requests for such materials to the information agent for the offer, which is named in the tender offer materials. Copies of the documents filed with the SEC by CTI will be available free of charge under the “Investor Relations” section of CTI’s internet website at https://investors.ctibiopharma.com/.

In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Sobi and CTI file periodic reports and other information with the SEC. Sobi’s and CTI’s filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements related to CTI, Sobi and the proposed acquisition of CTI by Sobi (the “Transaction”) that involve substantial risks and uncertainties. Forward-looking statements include any statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “goal,” “may,” “might,” “plan,” “predict,” “project,” “seek,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” and similar expressions. In this Current Report on Form 8-K, CTI’s forward-looking

statements include statements about the parties’ ability to satisfy the conditions to the consummation of the tender offer and the other conditions to the consummation of the Transaction; statements about the expected timetable for completing the Transaction; and CTI’s plans, objectives, expectations and intentions, the financial condition.

Forward-looking statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of CTI’s stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the Transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Transaction; the effects of the Transaction on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; that Sobi may not realize the potential benefits of the Transaction; other business effects, including the effects of industry, economic or political conditions outside of the companies’ control; transaction costs associated with the Transaction; actual or contingent liabilities; and other risks listed under the heading “Risk Factors” in CTI’s periodic reports filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q, and annual reports on Form 10-K, as well as the Solicitation/Recommendation Statement on Schedule 14D-9 filed by CTI and the Tender Offer Statement on Schedule TO and related tender offer documents filed by Sobi and Purchaser in connection with the Transaction. You should not place undue reliance on these statements. All forward-looking statements are based on information currently available to CTI and Sobi, and CTI and Sobi disclaim any obligation to update the information contained in this Current Report on Form 8-K as new information becomes available.

 

- 2 -

Item 9.01.

Exhibits.

(d) Exhibits

 

Exhibit
No.		   

Exhibit

99.1    Press Release, dated as of May 30, 2023
104    Cover Page Interactive Data File (formatted as Inline XBRL)

 

- 3 -

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CTI BioPharma Corp.
Date: May 30, 2023     By:  

/s/ David H. Kirske

    Name:   David H. Kirske
    Title:   Chief Financial Officer

 

- 4 -

EX-99.1 2 d480208dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders

SEATTLE, Wash., May 30, 2023 - CTI BioPharma Corp. (Nasdaq: CTIC) (“CTI”), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has cancelled the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) which was scheduled for June 21, 2023, and has withdrawn the proposals to have been submitted to stockholders at the Annual Meeting.

The Annual Meeting has been cancelled due to the ongoing tender offer by Swedish Orphan Biovitrum AB (publ) (STO: SOBI) (“Sobi”) to acquire all of the outstanding common stock of CTI pursuant to the Agreement and Plan of Merger, dated as of May 10, 2023, by and among Sobi, a Swedish public limited liability company, Cleopatra Acquisition Corp., a Delaware corporation and an indirect, wholly owned subsidiary of Sobi (“Purchaser”), and CTI (the “Merger Agreement”). If the transaction contemplated by the Merger Agreement is not consummated, the Board of Directors will reschedule the Annual Meeting for a later date.

The transaction is expected to close by the third quarter of 2023, subject to customary closing conditions. CTI expects that the current members of the Board of Directors will continue as directors until the closing of the transaction. Upon the closing of the transaction, CTI common stock will no longer be listed on any public market.

About CTI BioPharma Corp.

CTI BioPharma is a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product, VONJO® (pacritinib), a JAK2, ACVR1, and IRAK1 inhibitor, that spares JAK1. VONJO is approved for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. For more information, please visit www.ctibiopharma.com.

VONJO® is a registered trademark of CTI BioPharma Corp.

Additional Information and Where to Find it

The tender offer described in this press release commenced on May 25, 2023. This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of CTI common stock. On May 25, 2023, Sobi and Purchaser filed with the U.S. Securities and Exchange Commission (the “SEC”) a Tender Offer Statement on Schedule TO, and CTI filed a Solicitation/Recommendation Statement on Schedule 14D-9, with respect to the tender offer. CTI STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION WHICH SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders of CTI at no expense to them. Stockholders may obtain free copies of the Tender Offer Statement and the Solicitation/Recommendation Statement, as each may be supplemented from time to time, and other documents filed by the parties at the SEC’s website at www.sec.gov. Additional copies may be obtained for free by contacting Sobi or CTI. Free copies of these materials and certain other offering documents will be made available by CTI in response to requests by mail to CTI BioPharma Corp., 3101 Western Ave #800, Seattle, WA 98121, Attention: Investor Relations, by email at invest@ctibiopharm.com, or by directing requests for such materials to the information agent for the offer, which is named in the tender offer materials. Copies of the documents filed with the SEC by CTI will be available free of charge under the “Investor Relations” section of CTI’s internet website at https://investors.ctibiopharma.com/.

In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Sobi and CTI file periodic reports and other information with the SEC. Sobi’s and CTI’s filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

Forward-Looking Statements

This press release contains forward-looking statements related to CTI, Sobi and the proposed acquisition of CTI by Sobi (the “Transaction”) that involve substantial risks and uncertainties. Forward-looking statements include any statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “goal,” “may,” “might,” “plan,” “predict,” “project,” “seek,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” and similar expressions. In this press release, CTI’s forward-looking statements include statements about the parties’ ability to satisfy the conditions to the consummation of the tender offer and the other conditions to the consummation of the Transaction; statements about the expected timetable for completing the Transaction; and CTI’s plans, objectives, expectations and intentions.

Forward-looking statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of CTI’s stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the Transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Transaction; the effects of the Transaction on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; that Sobi may not realize the potential benefits of the Transaction; other business effects, including the effects of industry, economic or political conditions outside of the companies’ control; transaction costs associated with the Transaction; actual or contingent liabilities; and other risks listed under the heading “Risk Factors” in CTI’s periodic reports filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q, and annual reports on Form 10-K, as well as the Solicitation/Recommendation Statement on Schedule 14D-9 filed by CTI and the Tender Offer Statement on Schedule TO and related tender offer documents filed by Sobi and Purchaser in connection with the Transaction. You should not place undue reliance on these statements. All forward-looking statements are based on information currently available to CTI and Sobi, and CTI and Sobi disclaim any obligation to update the information contained in this press release as new information becomes available.

For Investors:

Remy Bernarda

Jenny Kobin

invest@ctibiopharma.com

SOURCE: CTI BioPharma Corp.

EX-101.SCH 3 ctic-20230530.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 ctic-20230530_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 ctic-20230530_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g480208g0531020019065.jpg GRAPHIC begin 644 g480208g0531020019065.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 30, 2023
Cover [Abstract]  
Entity Registrant Name CTI BIOPHARMA CORP
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0000891293
Document Type 8-K
Document Period End Date May 30, 2023
Entity Incorporation State Country Code DE
Entity File Number 000-28386
Entity Tax Identification Number 91-1533912
Entity Address, Address Line One 3101 Western Avenue
Entity Address, Address Line Two Suite 800
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98121
City Area Code (206)
Local Phone Number 282-7100
Written Communications false
Soliciting Material true
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001
Trading Symbol CTIC
Entity Emerging Growth Company false
XML 8 d480208d8k_htm.xml IDEA: XBRL DOCUMENT 0000891293 2023-05-30 2023-05-30 CTI BIOPHARMA CORP NASDAQ false 0000891293 8-K 2023-05-30 DE 000-28386 91-1533912 3101 Western Avenue Suite 800 Seattle WA 98121 (206) 282-7100 false true false false Common Stock, par value $0.001 CTIC false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, dei:SecurityExchangeName - d480208d8k.htm 7 d480208d8k.htm ctic-20230530.xsd ctic-20230530_lab.xml ctic-20230530_pre.xml d480208dex991.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d480208d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "d480208d8k.htm" ] }, "labelLink": { "local": [ "ctic-20230530_lab.xml" ] }, "presentationLink": { "local": [ "ctic-20230530_pre.xml" ] }, "schema": { "local": [ "ctic-20230530.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ctic", "nsuri": "http://www.ctibiopharma.com/20230530", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d480208d8k.htm", "contextRef": "duration_2023-05-30_to_2023-05-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d480208d8k.htm", "contextRef": "duration_2023-05-30_to_2023-05-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ctibiopharma.com//20230530/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001193125-23-156724-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-156724-xbrl.zip M4$L#!!0 ( 'V*OE:6ALP8/P, %D+ 1 8W1I8RTR,#(S,#4S,"YX MN[[^Z[G^[!^YM"PA4W5F@UCM*D%P%73.="S<=196-JF1#1 M^\/GSPY>Q#$0 P+YTJ;$7)]?9WD,Z&LEI5#"S9ANB 0QZW^Q\MO\+VV MGL&$2TXMAX):QPU\J(3,LWZOWT_3WKOD;1=F./7V(*>.9S D@Y2@X@#2?O9F ME U3.#J'3\&,@DM1\"Y6ETLCY@L'+]DK"*ACK127DB_A1"BJF* 2OK:47\.I M8@D<20D3#[/(TW)SQ?.DL7IC\\RR!2_H\V< F#!E,X4FJV(<^4PTB;B9&IEH M,R>Y,\0M2TY0*48M;@2+.M"_X^Y@L!)>8E? &;73 &HE/C_]#H(YP=;L-!KP/*N5AA BW+63+75P0%FPZ\7-P?2+_7&Q#L"H>YYAV( M%.K7#H073[%!ND[N0*X' 9".1B,2I!N406-]2&IAT*;.&3&M'#_1ICCF M,UI)1%7J=T6EF F>!RWLUH(KMZ:SKN&HF7-W00MN2\KX@].-C75?;$@W)3_. MS[Z&GHL./0 @M*$H2FTP/L3]L\WY_[S\Z YN#[>,?^?C3MWO%?VTPU 86AL_&D=_Y M<;MG?DHZ37#/M"IW'*R/EQ<3A'!Y=DNOQ3KA//C,B\'+\=6DXW8O5($$=OM-+% MLB9ZK%GEWZ+V^TCEGQ326YYB=R'84XM X&LR0?6?>ZFOB+94F0PYBI-.OWO0 28\]+F8GG26H>.&'N<=""-7^&Z M@IUT-BSL?#A]^^;X.\>!\\NKC^# +(H6X;#76ZU67?^!BQ"#9:0DPZZ'\QXX M3A8_&G^&/Y)R0_C$ N:&#.9N&#$)ORYYX \'!X-!OW_P2_?G?)IDKM8#WXW8 M$-[W#OL]%7@(_<'PIZ/A^SZ33600_>#]"G'6.0K @ M8!NXY,(5'G<#N,]:?@=7PNO"61# )YT6JCY#)A^9WTU5 R[^&^J_)KI[>/L& M0)U&$<;[3CKZ9*3G8CV101?E5#5[<-C+4CI/&>N=E-5AG- _.CKJQ4?ST2$W MQ2KQ?N^OF^M[;\;FKJ-.O_IV>6F9D _#>/\U>O$YK- @%$;HKYPLS-&[G/[ M.>QWUZ'?.=4%T[/C3EAPK;8@]C"4&+"2POIP7+V3QD>;A8IGZX@)GZ7*7[71 M2Z-FDCTDJAJ^6#)D7G>*CSV?<4W(0&\X>D-W^+WZXLL(%>]GDS"2KA=MUPOT M*4*9[8Q-G'0,2;WMAG3 M$;5) 7BJ +J$-;O-]9U'N&[S=B#?,V\I5;V+M3=3YED=D,VY+8%<:@2+8VQ M+M8C CDK %D%&I";ZSL/Q.3S6AT/@P$T'[<'_[D6+>5:'1)Y(J"I^S706ZEI"E#'[OK*5S]C M^ -/[O*\A-I"D581WF<-*P3;PUTJ3$NZ*@7;M6BY;]2*80A>X(=B),Y\7QD( MTW^NN6#]>N-@%&AU%,HLX9Y ^Q$H%*7%/]5_EVV K@2W@FH=TY@- _HO\-(, M^@-;] >O#OU!5?0'3: _^';HCU?8&/I$-BJC7^J%$/V1VKR58UR)%X&?3W\- MV!OLF*!_"B-#_KED0\#K,H 2="%:V*D-E*%>S04AYO'_AV_EG<1'+KR:EW6* M-%X#\$7&3-0_BR5#WZC;$/_)A0V%3E:-=@@:L5(V"37\$([#'8:1&_S-%_6O M<9H57L,HF$V9!F$KDFP,#*H-#4%2"50IRNN6S=DH&X#*7BP?9M4&)7/K +^= MT]:CK*;&8U8.L.SI$X,8_Y[4R#:?T?6X]Q%JQ63L0]=/EP=T,1J-6W)*[ M056639EM/6U=; *+(JR>M"Y0(^+W21XR??N'K!MJ>>L1ZSI]VV%[)YF>#Z:P MB!\@TZ]YR=N'A^H+AS*%EC"N8 KW1=I@O4^5"&]5!O)U("D$<25KT)LVD0?^ MA4Y(T;\*PR63]@-@T'D=8U!LT#P,._&$(U&@W=1@).4:G8^&')5.22U;-"^4 M]0>3,8^"VB^3/>6U_"+9C@$T'Z=X@6Q;BVI1D[U_I=0AEB=[<8RV7^-+8Q6: MM@-U+%W]2Q/N-_,)5EZ"/TMJ"5%SZV@X: .G08B(S%09$FEK*AMH-(]DU6XI M;HM_>$3M^1]02P,$% @ ?8J^5E ? MWS#/! 2"P !4 !C=&EC+3(P,C,P-3,P7W!R92YX;6S5FEUSXC84AN]W M9O^#ZMZT,S6.(=ENF) =2I(=IN1C@&T[O=D1]@$TE26/9 +\^QX9U,5@4IS= M=JQ9:EN!\%RN6S$4R:TY(L,0^I&)). M^+[MWQM_(K]MAFN3(7"@&DA"=0:*_+)@/&XWSYK-,#Q[WWBW*U- 33P2TPS: MY")HA0%V;)&PV3Z_;%^$I'M/;O,P@HQ9 KM:F:X5F\TS\D/T(\E5-U((X!S6 MY(X)*B)&.1E9RS^1OH@:I,LY&1J91I\:U#/$C6U4SL1?;?-O8MR3MV\(_F$A MAL%5B1MZM9'8B6K5P27EY>!OG18G_-RGKC &'P MQ_U@%,TAH3Y"0&C1WE#H)L[^4>^:NP@V!VU_S=HZCS2045[[$](B1WN83[[M MYILF/VSZK;"QTK%W;8;<5%5)#D.8$O/Z:=@OC!EE;,)D.JM MLR"C*REDL@Z,+KB1T2(!D=G7KHAO1<:R=5],)8I--A[)"]N>*YAV/ P=^3:: M\?3]$ -]KA(H6Z?XY= L23EX)-C)*55X_H@L[SW AH( 5AF(&&(;QB3P'V9] MO:&[/85E5*B"_1;GZ#1$C9E\#F)@9L2F>6-*U,S+@Q\^]R1.'-V)SA2-LF(9 MN#EGI+*-G$Z =[P24? M#6W2'<*,F? B>Z )G.JK7%NTMPNRJZ)"9*HB&Q7? M'E L?ANV/8*4*HSG1W.<^*QZJF126JKM:/(EOU+%H#H>U@0G X^DBDF%W;#% M(PN-EF1JS%-NCL$4E()XL"G"4;.Y4YQ8->0]OS&S$40+8_%V%S=30PPP4Y7V\N*Q^ MA76U>?! 7%]<1PQ;;!?.8+/7[3&6\51:14U](15]6C8_.\?F"= KWE;%-[@. MJ0II3UQ_6GN&+;;WSF"S][^15*E4>6U'6&+HR05.%^N>C"O>'_Y+J/HB/6XCMG*)KYI*N 5N%6U-275-&G M9>/._HOY#9(_S:6HN,X[U-67T:%7R\F=#9??T5\&HB>39"&VRQQ]*JPCXOH2 M.V+88G-G&V4D.8M8QL3L'B_&BAEK)_X$5Z*L+[ RMUM:Y^YLICPI,*<]GTM5Z ^GJ6)7&<(5KBW7)U9V/% M_L@?-B=CEO'*#S-\T=67VZ%7R\F=W9.QHN8IQ]$ZFN@H/2#+#!/ "[.6+^ MF<5O4$L#!!0 ( 'V*OE;PRR8'L1@ "^% . 9#0X,#(P.&0X M:RYH=&WM/6M3X\:RWU.5_S!%;DZQ57[#;L"PG.LU)NL3L#FV]VYROZ3&UAC/ M65E29B3 ]]??[IZ1+%DR&-; )F&K%FS-J*>GW]WSX/B?MW.770NEI>^]WZE7 M:CM,>!/?D=[5^YTHG)8/=M@_3[[_[G@60D?H[.FF(^3[G5D8!LUJ]7:LW(H6 MD\J5?UV%AFJCUFCLV(Z1+H>+0.BD]Y3K<<575]6X)=/=\STOFB>=;VYN*@0> M7W!"5<4WJM"I#+V$DI/XO5M7>E\RK]WLT4OUP\/#*K7&77,]DP$:M=I>%9O' M7(NX^R24DTQW>#"6?C#C:LXK$W^.^._5WN[5$ERT+,($H->KOUZ<#R=E MZ>F0>Y-DG"A4:[$ZK$)KW%%J?[]1_^F.*=@>R0NWZ_K6H:\'$Q:_?AB<+[N' MQ?V77:NAXIZ>^D"!$(0&(;TMUQKEQKL4D#*(1 90+"+WP3DH[]436L+@\JZI MKE 16YT5T;2=WU5-H^VZ7EA0S'=(W@5W\'<')1_.:Z:C_!L+D+.$$)9 M_!')Z_<[;=\+A1>61R"A.VQBOKW?"<5M6"6(K(KO52U0QMCQV'<6)\>.O&8Z M7+CB_8XC=>#R!6J!V#EAQ_*VB=V%LI^EXPC/?(8N/:,"3#KO=SY2T^^@?;]W M/$!R,1!74B-YPQZ? T(>_(0!A&P6MQ/"M^% 3*%7I(@?OZ-DEVMORWNUWT,_ M]6WGI#WJL@_=_N7'UN"BQ=K]P>5Q-8/5?5@.Q212@$?G=C+CWI58Q;*X_8%8 M]EK#T]:_[\-L.6AK+CP'_H=G+K]Z\&A3[FKQ0#(89K1A2,7=KN>(VU_$(L^M M7(<'HE:#?P>']<;A7AZ_ZHID*3$5"AR T/ =K6%3D\6"L1@9TB8:X?<[6LX# M%Q6/GLT4HH+&LAS;P\JM=N)FKB;*1Q'?V.X^@44_.:YFYV-GGYDQ?==^I,Q7 M,D!-2V[BW@;DCE\3Q+SDJW3PP50*Q0@%46@>V]U?L@Q;?1FQ+H0? $=])_D* MEE&%ISP4)TO7;4MS;FZDEX9/S<9CT(_?J+DUA/ZG#+M.]*A_U0HW\[ M)__XH?ZN=G1<#=8-M'?_0(U'#Y0"NP] 6'X"; JL*6OY?Z)9/TB^3_EZH<\J&H]:H,UR/3NV9T!EVVI\& MW5&W,V2MWBGK_-K^V.K]W &'=''1'0Z[_=Y7X=C8!HZ?N9Y!*!WZ7HF=5MH5 MUJB]W3]:-X *YD70QQZD\B#"%2<>#F M?IIBS*R#/JXB*B>O\O($\K(5_08+-.CT1FS0N>P/1B]O;RXCI2.(ZUGH,XBB M4>(,P>I[S%>L_G;7>?/R6/I3%LX$LV&^A/?C2)^U)B&#YOKAWOYZ/)^+NQCY M(#8#$?@J9+OQ=\$A\A$Z9.(:>C)%S<)YTUR?7<26X9+"IXZ)JAYJ(IC)EM_O M0(;== # '%Z?.7RQ (R$MW-RP1>&W7NU$L,7\P;EU9)LVY(T]K]+\0MR\HIU'NRK]+VVC;GM=FXYZ#5J ZJ/2G!G7#,=B FF-@Z3 M'I.A9F )0)O4JIUZE=5B6?T*NF!YBX]=P2;"=3'$H:HOV!G\'G#'B;_;H>Q4 M)[[K\D"+9OSA;@EA60P-,>JUVH^6=,V:1;-9BQ,W1$R97TXV']S;_Q%3^=!9 M:;T6*I03[EKBF@D7]K1P&@^ $^-<_,HJ0/AA<5=QEX!?B?)8"?X%2[^0S3?Y MM0\"LC'AZL2Z[+@L)4PL(TU-DB.V,A>0"< P;656=?>.R-98G:XW\14X._)3 MPQ \4-N/O% MVK[S5=X,S1W6)4(1*/\:AT5W=BI;6U8O*D8Q#*?Z_\D M-'QT^F"(?"9= 6UC,$V/*/65&P=[!^_64NRO3+@1O^W:0MF$*/5(*A[6R_6W M>WN']<8&9'P*;3_8DK(_UNMO)97>)?N 64 '1I&/3]:WDF3O\"J=YFLV_#Q[X:^3?>P^!BZCZ8[.:6^NH0H4]+6@6W'K,N*_^9+SQD,+WV Z?ZO#!X34Y\<'M0;]6V* MQ79LFIT;9O^! L++@+M,W(I)%,IK+ J >1&ZQ*#)C3#M9$ AA2XHUSYXI8% MQ;@%<=ZC.+7;J+U[DY>11\? YSYXL6@<-,H_U8N,2M$BQ L(T;+F M]8\?#AKUGXXT>'=7!#AGYM&DTQ($B2,'&GP3(M3S0]8* A>V#/Y:EWN*U:C[I&SGI#T3DR^T M;L(#<#A@1C&]&ONW;"Q<_P9YAHW(RONM"*TUFO+P5+JH+5*#ZH3"4&D68M5=', M5TY7*JN;50I6DW\SP/Z/1X5%E74.X;.2(3 4\[O(L]&[_NJ 9^S[[I@#,T,0 M/:3RX4_[^T=YGW%?YK:::+$L1]E7F^65/4,0F1EZ '2!&%!:LET$(&0[#?> M6OE=6:3$MGPF]BNT#Q78()GH"!/>N+L# @95SGT1F MW_TI9'9)# !MJ)$7V'NM?7V?E[&8:0S^4K8SJ^ZQ9-\+K;%?JQB(;U*AX:L2 M;%,)+I5 NXW[4FD_$?IEU9].'Q[6_X4,^+V2"50K3U)DBR7^/HN_@0(YY<;N M^,UV5*CX<6H$TUV?ZQ!ZKYLZ_I*;.AZSS+M!56/-; MTYT67E49X MFL[LIIS,V,3E6C_7FM]CB?C2%%, X4$C);>(NNTOMG]8VO3=GMFL]X8DV8__%0I1!9 EF'H M3[Z46, 5N^9N)-A_U4#4"I:T7F@+T[KY6^4T:OF8([7M;V6*&^]$+CRF"PJG M'?X':_- AMQE%UQ]$>%R+_)S1F5=S\%(5;#Q@DVH? X0OX#F"=J1M%*SEIK! MM"':Q4&OV)7R;\(9!KP!UK&Y9HZ82L_L4S:%PMI;EC_*L#S!L,=VD3,_'5&Q M,.XL:8=S@#N<<>EEPZBY,2XG!9S-CD_<#S3&#B/H'/P4FI7UYG([?.H4T]R( MM17NN]?.8P@_$X"V>?_9\KNGI4YW>H=#>!*N3 M?#+!+<'8&6]G<+ARM%GS<>[,B/9V>9(1I<6YDI:"A /KLJ5-3O9N<'+W3WQ$ MV*Q#VM7([[\#=U HF6*>$TQ\E HTQ@)8#X&&>\,7>L<<(\%[,9*@!!)%7S5_ M.*1_1_&$@MM,.:AJD;A[I7>[Y[Z__RY7\/K0'YQV!N5V__R\=3GL-.,/WW;! MJUXOK'@Q^@B"E"_EY#=5=T,Q-])Q4*G5*P4[P-/07JI =5?,;*9I-A%W\,"= MKK"'5'C>;<,(]SV6.UQ78G3J*KX/B+5]%51*C+/XW )+[3#&6."@T:@=P3OT MJ7[T!HPWUB2!!6 A<7N4 OO,M4 8$S^@Q7.3)H WGD;*DWJ&O776MQ.M'#&Q M(S6II(96!CSK[4R.96CP/CRLU&,?#Y89M\I8_ H>(_D*@S<">";& #%AZ'D M $Z>!Y8=Y1J:.,1+QJ5,\ H>%WT'6&XD"VMY7H21GQ#D!F 2%-3/@*]":;:+ M'2TQLEUCNMA)W^#I,'!I3H3@T1']*_*$F4NC'O, 9X)XH&MR%+_Q"!'<(>%K M[FKT-#-^#>Y1"*!8-)[C*K#9XY#&"B9$Q;@,0I4[#L]MQ[F/1@K\K18JH3_2 M%.0+0PL%7KH$#/%=%^3Q!N-?(")8+LD5">CP1C@@EZRO0 T\5(=K&:IHSEH? MV&X0C=TWB$#<"Q] _.9*8 . N)R@.MB3H _@J'*C'$U$"*ZAKPFNILJ?LQ D@!"! MWR664@4S_A*YDIT]@<9^%)OQB2F\4V0+41DABZ91D-870(R)6&%=0S4[$"@W M1H$ 2$?S.<%9)13XYKF.B9W#CPA](X$=0'BKI@4Z1(K+&6*JB+C/HU3+68K; MP 2],*N)ZVN*E&EZ,ZD<]D=$QTUQFH;#(-[_@1>H>P02-$=!QQ=Q,D NAW0+ MG!#.WP#7QB(B4,C)%(K67.!^Q(1Z'WP(A%E_RDY)HWRE#>F0C](#_<;\,FG" M -HUX.RX%DQ*!BKL4^![]W0JY;6!AO5\YH( H^T0H(0:R0,]4 &MALXI;[^3 M5T^Q>1("ECGN,D0I['K)[7!WH+$5]SXB:4^95 =$6LFQR?9--IQ>^6+QVAB1 M+3$3C;?&3%38*/\*^G!0!;FBDD13MDF! ;$,7 &A=@ M':J3-AM#DOUWZ:X:(M [[&&%]0M0+K1C4XGNAY(^%*Q/>"XE57; SDFNMCQ' ME/'PPTY[Z5:867UEM/S*:"\^V6&L^\469-0W/AW1-N.#]TC-MCH0AOB.F7PQ ME V6]$_+AW$T1#,$<@56[\,5<3"Z/ASUV[]\[)]#)F&N'.J//G8&K-O[GPXT MX;-!AWT:_-PYA4FP0:<%OS]VV*C3@S=8_^P,?EZT1IU!MW4^9+O=7OO\TVFW M]S/ LJWPVN6G0?MC:]@IL1: .&_AC4OGG=&((+#1H-4;7G1'H]8Y8=#N#$:M M;L]BDAGIM-_^=-'IC89OJ"=B,NR?=]O=46O4[?>J@PY>E 1OT%=SJQ/V9Q\Z M[=:G80??^(U][IZ?LW:_1Z-T+_"6DQ;TZ?;PIASSYN>/W?9'-OS8_W1^"B^; MB;>!%F>?SL]_@R?0M0,X_,9..^TNWLO$ND,@Q&D'H(\^0O_A9:<]PLFOD@OU M2%AI ;;$@EFRI0WC_6AA_B6%))J"TF@=N 8PMN@E/QU'$ MZA2\*\;^4B2N8XW.Q&'!AOAB\0>70&Q,HJ,@<*FI.#!!Z(9L":6L-EKG&8#7 M)!M@W)Y5<]J4?R,@/@P%-J7NMJO@]G)IS9Z=H47&S-W&^$0!K&6!O48G!GZ- M+!,T 3TK["Q'(:!KO#E.%_"=&(Y@EC.)F3?G#J!YS:5+Q0*,HX%E\";: M\R M3(D_(J'A+6B><_3+?ISX7682O]7C8>R'@QK$C?;$4HE];C$ZG@.JC1M1*5<# M)W<-;V A&,49 PN*,06-A%D6M?]WZN)9O'>VA.2 ;B9DP,DE6"(-=42MYUOQBPE0,(D9*5T5D\1I@&3$A(W)OJ0X M,1L@X)T?X$.6FT&L]\A3)XZ*M:D>6C5+9 _WL"M/A&DAQ'L6=;-:E1:8SE_C M^_0Q:1=H;N4_YL2*"#VO[80#"&AN>=(IVQ#6J+2#*^P.'TCIEAPR7=S M@D!G9813;J?]M'3$YL 2S(:F9*X(?T4EYWC.925")<4U/(+@Y1I/E)EF2":"JNG8I>3B46;F-#4^*V+-I@Q)>J85@_"JRBONG8-LR%BX(9^XQF"0Y+^AN,LO5I^:,SNK3*Y^[J\_ M^8> MH;BM/@Q<[N6>*8$W->0?^_\IP$D+\67U68CV/ _ )[^71Q8]0^Z9'[FYF4Z* M'NI9<5>36J?K*%J""G"%\1@67$T>W[49WE>H0"G6@8R96Q$LNX*26J"AE8J_ M[RK-4YU41^ %6IQZQ,=^%*;C6,LT%I.#9J MQE-N!B!ET(Z*T5T6LR3>0A][25JA->6V')Q5[XL*#^&!3U4N>8W'K@U4NZ?7 M+ W8 %67[)F_>'TWF>02$&OT3(2%!H5-."Z0PTM8SJ2['K59]-;P"C$2 :2B8G=AFH6MZW-[>)GNQEOGI48$*2># MJ[W#@UMM*MD2N(U!\]<(W&MGR*S U+&,G6]'-ZCBY&LF QNU M"W,[#:D72< X DK@&B8:5(\*(*I@'L!7,V*B>@MS*03I7FR_8G%1N,0##*(< M\>RTED[Q_10$\*>U1R=)& M+AL5ZZEWDM45EB*6T N6&"0*K.?9:DZ1J%;8;W[$3(Q/2@IN:D*UHHB*)1*7 MR9E9"M/I**_"6JY[ERO#$ #_. @MXJ1K&5:F<$4F*4;8JA]BC]-8+E+$3\"D MZ8G+Y=S<>["\'@$WV@6X\IFKPME$,K7*M(4TG&O:G9<>9XP2@^H4S\8&;W?% MX+GHC:7#MX.U^^BV?.E401Y29@U6CB?PFE"];GN[<]O;X9]ZVYO=P/426]YV MG3(-3BBBQMI3BO:#8R@>?]OD/.&:HXRF\7#ONHX%6=,QIM9Y?I(*;G&I9>[;E4<<<-]+@#:C$XK_61Y)<1LG] MJC-B2W)EM'PID06*ES_1%5^0A2T%%$LU0^2!J@<2TGCF6\OS)K:09V:OZM.( MBCG(Q9GYLW7._D&M43MPQ.WA8;TR"^=T^!TRN4&\&;=P1V"\"1@L(U]+P;\+ MM^JU_2=E5AOK".P29LBZ:- X%2[9*0\YHTN#=TVL:_G4I3\RRO"OC+Y)*U/B M-/^L<>_>:]S[K L)F_T=NN[/O=;HTZ#SF((XP9,>7K&,]YL\+$*[7-FOBWM MI++);?Z48*:8DCHI&&\[R)P4@_1^86K)CLE,33T#A\(R)A# ILVX,4;,N#N- M5].I/F0[F(W)6'E&<,"OF:]@ O$5 6AI!90=]/XL.'!)5W7E+Q,(AW M 'J[?=3V,_%N/IQY#J=UQ[P?>I[ZN2$O'?_>O?%VP9:T>_Y.Q2;1"6KC7>$) MM>?CDZ?J^T)Q3\P^_*-MS7P,^&>2+(JG/BR:3X?SPR[6N.=HZP,]8E57(2J\ MAO<_5M@O4NDOXMGOU?@+F!\2$KS.X0G%),>F5Q8]F$5TT\H3\J@]DV(*&5:\ M^:-/]_2KOU1.M7]G3G5<'?O. I[,PKE[\O]02P,$% @ ?8J^5N@/./-? M#P :2T !$ !D-#@P,C X9&5X.3DQ+FAT;>U:;7,:QY;^3A7_H4NIF[*K M $EVG&M+6+4(D$6,A!90O-YOS=! QS/3D^D9$>ZOO\\YW3,,"-E.UD[=#YM* MV6:F^_1Y?C.\:%_W.[V+>JT]'4R'_8O^_S3?O&F=MH_=3SP_]@M$ M^W+4^R@NWW5'P]'X[=&'Z\&T?W0AZC4LZJHX4^E%NS?X54RF'X?]MT=K/<]6 M9Z];KW1\)&2HE_';HU MLB.F=5^%C'2X.9OJ2%EQJ]9B;"*)DSK#P;O;MT>I7JYP5/ORHO_'2L]T M)D@LT3Z^O&@?WUU4&*A0?P'J>_P\8N?HXL=X9I-SH@+!GY+CP#Y2%'8,;MZ) MR;C[]FCYT^N3%R>OER>O7I[B'R>G;TY^?M7Z+5F2$-.W1\/1NY%3UB[#E9.8 MXV^ELH!MR#KK3@?B4IN[E4PC*3IQ;/(XP*:NQ%]A*#-M8F$60F=6O#AY\9*6 MY#(4-TIE.E[2JTEF@D\K$\Y5:DNU/Z&P;R(&\3WI=Z9PVX;X(.VJU1 W'N@\DP'>(*7B8PW8#G(K9K7:]!8ME)BKAY4:)(( MRA8RGE>(Z'^5>HT-%HD,"E&9FM.^5"8:XBY,*F:A,?-FJF &O O()*EMB,S, MY08DG:UHD\Q@(+&2UBT*0T?JJRSVC!8ZH7=7>OG%>J6#E5B#N U6:IX3<>+N MESQ63LLO3AOU&IW58$&)C[7.5O-4KITJDM0DQLK0@G>\?E!BIE0L;#Z+=,9R M&V&K3$$@VK?+4.M[Q\?%]-&9+ PSN]7L/%?$,!@D6R\-+PDH*.3-DVK;_#X:M"0QSU1P*&74P&H;'*"U^O92L-F7[/ M99JQJWLO@4U^PPY>G\,9([(.[70^"D,2:=MB8SCJUF$6:2#(TY04&:EH1I'O M_?PI_9%5=(P A-/.RUIVF3&BWFK>/:?4%T9KG MA&._CFY_&;4G]P?*T7^^^L>Y>% IJZK)%?09+(4"-%5+U)_8=(&L(8,4H13K M&=OVB(3O?7\:G#NL&X\_ZT7M,Q5\$F;;@@ XL '5I^VG),L+D\FZQ# M%P1*9FP':%P"H#*7Q('$B/8(F \%-P56KU!P-U-M/T$VS<&.AU91I-./9\CT M63,QX2;8@'"D)8DF:1&_4=;B%/*2;)6::&:*9<]%M($S+/0L17CZTZ5@! X5 M82S"'$8,S5J\.A$_9N23Y^+TA)5:KWV]6M\XE1X/6V*ZPDF4; )9 &"IFIQ3 M.HR*1(S4#R$X6_)K(W>D.BG"(@CA"Y"L7BL<6\<XZW<'5H-L!YN5SSJW>4^)MJ+ ]=DU$7%F$ M<*HJQC2)BF%T29C %G?(2$>FB@L:MT"OR6BM 1[>/[BQ8UK(QQQVA%@7>^,447Q?^W$\BR"=4N JOH$?31 MHT0N57.&"/C4G"DPH\YDN)8;2TU9^WHL)H/_A6>]/"I(C[)\2Y*S(08(.M,[%[?EBQ=QIQA8BC+NGOR(Y<5E4[ A>Z,^A+QR[^$X"R MA2*=NW/>XV8.;)>5^(M7KA+W,+6[1;O\5PD>2(_R'R&G*%^%KGBG E5IRIF" M:_\%U:^4 7V]C.Q**=(:U# Z*W-NL98[,[0]PJXXC7@C5RNDEA@=X+GAJG/N M.HK27"PT]4\,)(0^]ZU)2TP42D!83SDXZ?^!M4!!@&<4:6N)GTH%/^EWBP9) MBJE3\8@9G8!Y5Y-CQZ0HLJ>CLA&HU]SQ:&$JPAZ/E5/^W,E^F,P74__I3[WF MFT:1]%E"J"OQ=7&VYP\.CM'_==]?CX:]_G@B.K<],9I>]\=B=( R@\YP(IX-;KO#^][@]AUH^;?3 M4;UV=S_N7G>E9VC M>J/N_0U0;?*<5Q(KD]%PT!U,.]/!Z/9XW.^.;K"@QS\A'8ZB]>*RW^W<3_JT MXR.PC^V$/FYWD72CCZGXX M_(@G6-H'#Q]%K]\=3&C+8 )-]/J@/KW&^LE=OSNMUZ"U?851*"GO,3!,X9JN M:2NJR*'*?(&3F^EJCP@^.X: MA:J# =<9^E#_^9RTB;8_4_2&Z@$4FZVE>6B)"NX[ 9W@8,;)[NM;UL!LPQ66 M=,4/@Q->0:&H1!YI"(JE9IZJ)WO \&QQ(K.5I+!>A'0HY(/4H9R%?"I77C'# M@?$6HSI(6>S"ZTA2ZVH.S28;XN7IR:GXH"C7QJ+SH,0/KT]. *VHU;,0.OW0 M$6]>G_+\K0.?C4D99\B!#]@"Z<;*37 MSW(4'T6S0G[_7Y6RBJJJ!ND#RUQ; M791KS"8IT>9LZD(I'M5T-=UR[5HT%*RCAI\>4A:249'^]I)C290JYJJ;[OM) MF3C@&EZSOCV?577.YJ8">44MHR_CMRGDL79<1J$>IDA_?OQ+OL?]3XS^H^*$ MJ$M769;8L^-C[:G91U7J,9>IXKM/PP?0O(^#PBK_,?B&KFR+%V5!0*Y.%A4) M[&[0!X&SQ*2^'7=G5QVK:O>6*(:D9!Q/K?@)HO!;N^LHDB>HUE0]I %KR\_ MPF'0JHPQ"I&;J4(CI:A_0Q7SH -?JWB@*AP#X15[U)EM: 3AS]\#K;^A'D9K MM9;IO#DTYA.C76&$+U[0?*/R]T"!RZIA*&'60L^:W;)6N*<#PXJ_;*\0J'RK MC))]1J1Y.X^"MT$^W<[TRH'Z2F8T'D&?_J!XDIQ)-XB@88:S*%VH< 10(N(6 M]2EF=1R$.4%]O*D^]G(6_?7:I'/K6:+# HUV6C4\X+CG,Q7"M_8> E-T]&BI MFY[N/B-\BN>[SY9&AOY)O>8>(2_NKHGHWG3W41+*>.\)6CR]?R),\=LC-JQ2 MGW:?N('=WE:3N>'/[F/"\+TG)@_WA H>/[*KRK-"TF)$[%?RC$+#465*11-Y MI1M'#PYU8HT=./FR^2N/)$UEJX6,(R.*:Q'JI(!G=N&JG>UDO$"A\A+!N_:C M1%G$@D/(+0%NZ)ZB4(F$\\/L;B?^".2L!$@:V8:J'!7MT-G#77(C" MC6\$5G2/Y$>>K@IDW*22LB*&OUB5(L[I,H@\^$EHGC+))UX[D:I,DP=[QA^S M2SS6:SL>NW_[]V4H:/A[4E\ZK:@0.=MC2Y:QCE"KWD#M1WG$%XWG![>OS!H* MCC=[=>I.J\A%L:?JKC?<+;$OO_F@KAZQJ=0%13FU14GPJL"B)^=;FW '< M_IX'B4(NMP>N_\X57JD(=\4Z!P0A%. M^B;/@S:R#1-!*N+;CH:8HWC8.&]H?$7T1)!D7(3A>5C]_3 M8"@M6H>53GRY2=YB-HHCC%U@ED,5E%HH'<3L.QH&,N0V2S=(&S".B5"+ M\W41',S?'I;N1!] Z+DJSG7WBMMD2W&;FO"\>JE+:(+AN$W:SF M ()S7WD74WS7P';:]B<.>?Q-\+;%7"G) KI29$RW9%<.9GTY@@BL)L[]!NBO M34BKJO47ZO5:01+NBM01?7F&^;KYOIQ@^EM^ /B?)G-ZTOSODH[[G"-VN/OG M"6T9^DL]YU^8X1;GE9,I'KGYPNNK!LZ\NNQE#K;06^H'AN2:OSV)_3#BD*>V MQ$>3"U?\2;^^(),,T&H=01IWN#)GLIBSE%GM 7+H^&2+Z!>O*F1-)] MQKJZA>X_"1'MEK/O_Z68:[++21LR_8$/3K]U7SU6T49<(G_ >-+=?W['>O,7 M%<-H[V'&^#/J_"9'M>\O'L\DRZO>[SY!FXSNQ]W^V>>^J'FJ7X'51[V/>,B? M6/\;4$L! A0#% @ ?8J^5I:&S!@_ P 60L !$ ( ! M &-T:6,M,C R,S U,S N>'-D4$L! A0#% @ ?8J^5J3T?M^!!@ MND8 !4 ( !;@, &-T:6,M,C R,S U,S!?;&%B+GAM;%!+ M 0(4 Q0 ( 'V*OE90']\PSP0 $@L 5 " 2(* !C M=&EC+3(P,C,P-3,P7W!R92YX;6Q02P$"% ,4 " !]BKY6\,LF![$8 O MA0 #@ @ $D#P 9#0X,#(P.&0X:RYH=&U02P$"% ,4 M" !]BKY6Z \X\U\/ !I+0 $0 @ $!* 9#0X,#(P.&1E >>#DY,2YH=&U02P4& 4 !0! 0 CS< end